Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 8, 2025American Journal of Clinical Oncology

Real World Radiographic Response Rates and Preoperative Attrition in Patients With Nonsmall Cell Lung Cancer (NSCLC) Treated With Neoadjuvant Chemoimmunotherapy

View Full Paper
Ask AI
Bookmark
Share

Authors

CFCole FriedesMIMichelle IocolanoNYNikhil Yegya‐Raman

Discussion

Loading...

Member takes

Overview

Observational analysis found a 58% surgical intervention rate in patients with NSCLC after neoadjuvant chemoimmunotherapy, indicating challenges in patient selection.

Key Points

  • The rate of surgical intervention after neoadjuvant chemoimmunotherapy was 58%, based on patient eligibility for surgery.
  • Toxicity from chemoimmunotherapy and surgery resulted in 42 and 19 adverse events respectively, with some being grade 3 or higher.
  • Analysis of a single-institution database focused on patients with stage II-III nonsmall cell lung cancer.
  • Further validation in external cohorts is needed to improve patient selection for curative surgery.

Cite This Study

Friedes et al. (2025) studied this question.

synapsesocial.com/papers/690e8b6ca5b062d7a4e7355chttps://doi.org/10.1097/coc.0000000000001260
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world experience with neoadjuvant chemoimmunotherapy in resectable NSCLC: A single academic institution experience.2026
  2. 2Real-world outcomes of unresected non-small cell lung cancer following neoadjuvant chemoimmunotherapy2026 · 1 citations
  3. 3Clinical outcomes associated with neoadjuvant therapy for the treatment of resectable non‐small cell lung cancer in real‐world practice2024 · 8 citations
  4. 4Chemoradiotherapy versus surgery after neoadjuvant chemoimmunotherapy in patients with stage III NSCLC: a real-world multicenter retrospective study2024 · 14 citations
  5. 5Real-world adoption and pathological insights of neoadjuvant chemoimmunotherapy in resectable NSCLC: Single-institution experiences and perspectives.2026